Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
9.53
-0.02 (-0.21%)
Mar 31, 2025, 1:06 PM EDT - Market open
Alvotech Revenue
In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth. Alvotech had revenue of $153.34M in the quarter ending December 31, 2024, with 177.38% growth.
Revenue (ttm)
$491.98M
Revenue Growth
+426.84%
P/S Ratio
5.20
Revenue / Employee
$492,470
Employees
999
Market Cap
2.88B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ALVO News
- 2 days ago - This Is a Test From GlobeNewswire - GlobeNewsWire
- 4 days ago - Alvotech (ALVO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - GlobeNewsWire
- 4 days ago - Alvotech Reports Record Results for 2024 and Provides Business Update - GlobeNewsWire
- 4 days ago - Alvotech Reports Record Results for 2024 and Provides Business Update - GlobeNewsWire
- 5 days ago - UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 5 days ago - UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 11 days ago - Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production - GlobeNewsWire